ESC-ERS 2022 Risk Table Calculator

ESC/ERS 2022 Pulmonary Arterial Hypertension Risk Table: Explanation and Clinical Context The ESC/ERS 2022 Risk Table provides a multiparametric assessment model for estimating the 1-year mortality risk in patients with pulmonary arterial hypertension (PAH). It integrates clinical, functional, biomarker, and hemodynamic data to categorize patients into Low (<5%), Intermediate (5–20%), or High (>20%) risk groups. Key prognostic parameters include WHO Functional Class, six-minute walk distance (6MWD), brain natriuretic peptide (BNP) or NT-proBNP levels, clinical signs of right heart failure, presence of syncope, and evidence of clinical progression.

Patients classified as Low Risk are expected to have good functional capacity (WHO FC I–II), 6MWD >440 m, and BNP <50 ng/L, with no right heart failure or syncope. Intermediate Risk patients exhibit moderate limitations (WHO FC III, 6MWD 165–440 m, BNP 50–300 ng/L), while High Risk patients (WHO FC IV, 6MWD <165 m, BNP >300 ng/L) often show overt right ventricular failure and recurrent syncope. This model supports treatment escalation and follow-up strategies.

The primary therapeutic goal is to achieve and maintain Low Risk status. Reassessment should occur every 3–6 months, and dynamic risk changes provide valuable prognostic insight.